Hospital
Virtua - West Jersey Health System, INC.
Virtua - West Jersey Health System, INC. was paid $255.73M by Medicaid between Jan 2018 and Dec 2024, across 480 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoVIRTUA - WEST JERSEY HEALTH SYSTEM, INC.
VOORHEES, NJ 08043
VOORHEES, NJ 08043
33aNPI1528064409assigned 06/24/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$255.73M
24GClaims3,372,937
24DCodes billed480
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#4 of 93
Median peer was paid$30.60M
This provider vs. median8.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 383,036 | $31.29M | |
| 2019 | 415,967 | $32.57M | |
| 2020 | 341,586 | $27.29M | |
| 2021 | 498,653 | $38.17M | |
| 2022 | 581,612 | $44.06M | |
| 2023 | 631,022 | $43.26M | |
| 2024incomplete | 521,061 | $39.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 158,358 | 145,826 | $74.91M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 127,082 | 119,465 | $46.24M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 10% | 89,961 | 7,484 | $26.80M |
| G0378 | Hospital observation service, per hour | 5.4% | 22,282 | 17,604 | $13.80M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.7% | 26,579 | 24,522 | $9.44M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 3.5% | 39,610 | 36,523 | $8.85M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 42,655 | 40,750 | $8.00M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 14,273 | 13,763 | $2.74M |
| A0434 | Specialty care transport (sct) | <1% | 5,844 | 5,435 | $2.54M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 62,368 | 17,711 | $2.15M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 143,993 | 37,508 | $2.14M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | <1% | 10,777 | 9,629 | $2.11M |
468 more codes
| 59025 | Fetal non-stress test | <1% | 12,820 | $1.85M |
| 90863 | <1% | 21,006 | $1.71M | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 25,610 | $1.62M |
| OP278 | <1% | 1,784 | $1.59M | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 9,369 | $1.48M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 5,598 | $1.46M |
| A0425 | Ground mileage, per statute mile | <1% | 67,321 | $1.40M |
| OP272 | <1% | 14,119 | $1.24M | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 17,671 | $1.24M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 36,502 | $1.20M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 990 | $1.15M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 64,536 | $1.14M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 16,307 | $1.13M |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 3,692 | $1.12M |
| 90791 | Psychiatric diagnostic evaluation | <1% | 6,247 | $1.06M |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 8,346 | $1.03M |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 13,943 | $1.03M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 27,644 | $998K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 5,125 | $991K |
| OP370 | <1% | 9,447 | $952K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,529 | $932K |
| OP259 | <1% | 230,366 | $813K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12,404 | $813K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,533 | $797K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 43,751 | $771K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,589 | $764K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 22,431 | $760K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 44,843 | $750K |
| J2350 | Injection, ocrelizumab, 1 mg | <1% | 44 | $682K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 718 | $662K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,610 | $594K |
| A0433 | Advanced life support, level 2 (als 2) | <1% | 2,247 | $580K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 823 | $542K |
| 97161 | <1% | 13,740 | $513K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 106,652 | $497K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 26,895 | $494K |
| 71045 | Radiologic examination, chest; single view | <1% | 22,429 | $487K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,194 | $460K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 11,648 | $418K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 5,792 | $413K |
| 97113 | <1% | 10,693 | $401K | |
| 76770 | <1% | 1,743 | $400K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 100,829 | $381K |
| OP258 | <1% | 76,896 | $375K | |
| 76813 | <1% | 2,414 | $339K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,201 | $329K |
| 0002A | <1% | 10,335 | $328K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,257 | $324K |
| 76830 | Ultrasound, transvaginal | <1% | 4,094 | $321K |
| 95806 | <1% | 1,613 | $313K | |
| 0001A | <1% | 10,613 | $312K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,667 | $307K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,521 | $301K |
| 71250 | <1% | 2,003 | $300K | |
| 93017 | <1% | 2,040 | $281K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 12,510 | $266K |
| 0240U | <1% | 10,157 | $266K | |
| 93976 | <1% | 6,063 | $261K | |
| 76818 | <1% | 1,374 | $260K | |
| 88342 | <1% | 9,251 | $256K | |
| 76801 | <1% | 5,480 | $246K | |
| 70486 | <1% | 2,048 | $240K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 23,532 | $240K |
| 93970 | <1% | 2,434 | $208K | |
| 97162 | <1% | 6,117 | $207K | |
| 73630 | <1% | 7,618 | $203K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 23,527 | $198K |
| 93971 | <1% | 4,213 | $192K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,508 | $172K |
| 36415 | Collection of venous blood by venipuncture | <1% | 140,137 | $172K |
| 73564 | <1% | 5,152 | $166K | |
| 90837 | Psychotherapy session, about an hour | <1% | 3,343 | $160K |
| 73130 | <1% | 6,466 | $154K | |
| 73610 | <1% | 6,506 | $151K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 910 | $148K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,802 | $148K |
| 70496 | <1% | 798 | $145K | |
| 95782 | <1% | 228 | $141K | |
| 84484 | <1% | 32,045 | $140K | |
| 72110 | <1% | 1,642 | $139K | |
| 80076 | <1% | 43,063 | $138K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 313 | $134K |
| 76870 | <1% | 1,503 | $132K | |
| 73030 | <1% | 4,801 | $130K | |
| 80053 | Comprehensive metabolic panel | <1% | 24,938 | $129K |
| 74018 | <1% | 3,797 | $129K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 160 | $129K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 167 | $129K |
| 70498 | <1% | 782 | $128K | |
| 97165 | <1% | 3,821 | $124K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,354 | $119K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 38,769 | $113K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,979 | $109K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 503 | $108K |
| 88313 | <1% | 4,637 | $103K | |
| 72100 | <1% | 3,177 | $102K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 10,590 | $100K |
| 97164 | <1% | 2,641 | $97K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,488 | $89K |
| 87070 | <1% | 21,341 | $87K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,192 | $86K |
| 90715 | <1% | 5,739 | $85K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,317 | $83K |
| 73110 | <1% | 3,174 | $83K | |
| 85027 | <1% | 23,823 | $81K | |
| 80306 | <1% | 12,194 | $80K | |
| 83880 | <1% | 6,220 | $79K | |
| 83690 | <1% | 36,027 | $77K | |
| 81001 | <1% | 68,411 | $77K | |
| 70491 | <1% | 459 | $76K | |
| 76536 | <1% | 608 | $75K | |
| 93325 | <1% | 321 | $75K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,717 | $73K |
| 74022 | <1% | 2,151 | $70K | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,402 | $68K |
| 95816 | <1% | 520 | $67K | |
| 76775 | <1% | 1,196 | $67K | |
| 76820 | <1% | 1,055 | $66K | |
| 87581 | <1% | 3,573 | $64K | |
| 84703 | <1% | 43,225 | $63K | |
| 93798 | <1% | 1,473 | $63K | |
| 87430 | <1% | 19,009 | $62K | |
| 86850 | <1% | 8,902 | $62K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 773 | $62K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 679 | $61K |
| 85730 | <1% | 24,926 | $61K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,217 | $61K |
| 87486 | <1% | 3,494 | $60K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,513 | $60K |
| 82962 | <1% | 20,977 | $59K | |
| 87040 | <1% | 9,597 | $56K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,523 | $56K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 26,986 | $55K |
| 73590 | <1% | 1,975 | $54K | |
| 85610 | <1% | 26,615 | $54K | |
| 82248 | <1% | 19,363 | $53K | |
| 88304 | <1% | 2,495 | $53K | |
| 73090 | <1% | 1,622 | $53K | |
| 80329 | <1% | 4,814 | $53K | |
| 74019 | <1% | 1,454 | $51K | |
| 86900 | <1% | 9,851 | $51K | |
| 83735 | <1% | 20,045 | $51K | |
| 73502 | <1% | 2,265 | $51K | |
| 72040 | <1% | 1,428 | $50K | |
| 73560 | <1% | 1,877 | $50K | |
| 76825 | <1% | 214 | $50K | |
| OP710 | <1% | 2,396 | $47K | |
| 80320 | <1% | 6,763 | $46K | |
| 83605 | <1% | 7,515 | $46K | |
| 0003A | <1% | 1,392 | $46K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,827 | $45K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 16 | $44K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 383 | $44K |
| 88341 | <1% | 550 | $43K | |
| 76827 | <1% | 213 | $43K | |
| 94664 | <1% | 6,403 | $42K | |
| 73140 | <1% | 2,422 | $41K | |
| 88307 | <1% | 633 | $39K | |
| 74183 | <1% | 54 | $38K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,447 | $38K |
| 87077 | <1% | 10,581 | $38K | |
| 87186 | <1% | 9,749 | $38K | |
| 80061 | Lipid panel | <1% | 6,309 | $36K |
| 84702 | <1% | 7,018 | $34K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 30 | $34K |
| 86403 | <1% | 5,986 | $33K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,846 | $32K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,723 | $32K |
| 73080 | <1% | 1,198 | $32K | |
| 81002 | <1% | 16,263 | $32K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,076 | $31K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 28,851 | $31K |
| 81003 | <1% | 29,432 | $31K | |
| 87631 | <1% | 708 | $30K | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 258 | $29K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,066 | $29K |
| 88312 | <1% | 1,080 | $28K | |
| 90675 | <1% | 135 | $27K | |
| 86703 | <1% | 2,206 | $26K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,490 | $26K |
| 86901 | <1% | 9,884 | $26K | |
| 85379 | <1% | 8,653 | $26K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,177 | $26K |
| 36430 | <1% | 284 | $26K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,410 | $25K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,936 | $24K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,886 | $24K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,989 | $24K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 195 | $24K |
| OP229 | <1% | 464 | $23K | |
| 77412 | <1% | 114 | $23K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 475 | $23K |
| OP720 | <1% | 190 | $22K | |
| 73700 | <1% | 134 | $22K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,958 | $21K |
| 86780 | <1% | 3,019 | $21K | |
| 70360 | <1% | 582 | $21K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 7,553 | $21K |
| J1815 | Injection, insulin, per 5 units | <1% | 4,998 | $20K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 482 | $20K |
| 95800 | <1% | 207 | $20K | |
| 72070 | <1% | 665 | $20K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,310 | $20K |
| 94760 | <1% | 8,745 | $20K | |
| 87205 | <1% | 3,996 | $20K | |
| 72050 | <1% | 253 | $20K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 383 | $19K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,197 | $19K |
| 59050 | <1% | 159 | $19K | |
| 71101 | <1% | 1,012 | $18K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 386 | $18K |
| 77336 | <1% | 186 | $18K | |
| 97116 | <1% | 2,151 | $17K | |
| 86803 | <1% | 1,307 | $17K | |
| C1776 | Joint device (implantable) | <1% | 25 | $17K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 3,406 | $16K |
| 90375 | <1% | 13 | $16K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,008 | $16K |
| 85007 | <1% | 8,786 | $16K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 118 | $15K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 318 | $15K |
| 70544 | <1% | 76 | $15K | |
| 77334 | <1% | 19 | $14K | |
| 0072A | <1% | 404 | $14K | |
| 0071A | <1% | 399 | $14K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 576 | $13K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,430 | $13K |
| 82728 | <1% | 2,146 | $12K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,522 | $12K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,907 | $12K |
| 94644 | <1% | 688 | $12K | |
| D1110 | Prophylaxis - adult | <1% | 812 | $11K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 371 | $11K |
| 84100 | <1% | 6,026 | $11K | |
| 73552 | <1% | 476 | $11K | |
| 82607 | <1% | 1,893 | $11K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 228 | $11K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 12,570 | $11K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 41 | $10K |
| 82550 | <1% | 4,081 | $10K | |
| 97168 | <1% | 252 | $10K | |
| 84439 | <1% | 2,492 | $9K | |
| 74174 | <1% | 57 | $9K | |
| OP255 | <1% | 447 | $9K | |
| 80074 | <1% | 658 | $9K | |
| 73070 | <1% | 330 | $9K | |
| 70490 | <1% | 56 | $8K | |
| 73060 | <1% | 320 | $8K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,548 | $8K |
| 93356 | <1% | 480 | $8K | |
| 90686 | <1% | 1,031 | $7K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,218 | $7K |
| D0120 | Dental checkup, returning patient | <1% | 559 | $7K |
| 82803 | <1% | 1,204 | $7K | |
| 86140 | <1% | 4,045 | $7K | |
| 97166 | <1% | 340 | $7K | |
| 86787 | <1% | 607 | $7K | |
| 82247 | <1% | 3,065 | $6K | |
| 83550 | <1% | 1,855 | $6K | |
| 72141 | <1% | 24 | $6K | |
| 86618 | <1% | 698 | $6K | |
| 73660 | <1% | 353 | $6K | |
| 87340 | <1% | 867 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 113 | $5K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,279 | $5K |
| 97760 | <1% | 313 | $5K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 16,893 | $5K |
| 81025 | <1% | 2,447 | $5K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 435 | $5K |
| 84156 | <1% | 1,637 | $5K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 682 | $5K |
| 72195 | <1% | 12 | $5K | |
| 76642 | <1% | 38 | $4K | |
| 82947 | <1% | 3,230 | $4K | |
| 82310 | <1% | 3,210 | $4K | |
| 83970 | <1% | 202 | $4K | |
| 97602 | <1% | 137 | $4K | |
| 80164 | <1% | 619 | $4K | |
| 99241 | <1% | 57 | $4K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 148 | $4K |
| 0031A | <1% | 119 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,603 | $4K |
| 82374 | <1% | 2,876 | $4K | |
| 82746 | <1% | 831 | $4K | |
| 82565 | <1% | 3,039 | $4K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 334 | $4K |
| 84295 | <1% | 2,898 | $4K | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 165 | $4K |
| 87507 | <1% | 70 | $3K | |
| 84520 | <1% | 2,977 | $3K | |
| 86762 | <1% | 502 | $3K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 3,843 | $3K |
| 0064A | <1% | 88 | $3K | |
| 82435 | <1% | 2,864 | $3K | |
| 82272 | <1% | 1,181 | $3K | |
| 82150 | <1% | 1,225 | $3K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 178 | $3K |
| 92610 | <1% | 115 | $3K | |
| 73562 | <1% | 60 | $3K | |
| 0004A | <1% | 101 | $2K | |
| 85652 | <1% | 2,693 | $2K | |
| 73521 | <1% | 62 | $2K | |
| 97163 | <1% | 90 | $2K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 152 | $2K |
| 94729 | <1% | 63 | $2K | |
| 72131 | <1% | 13 | $2K | |
| 87147 | <1% | 1,011 | $2K | |
| 84075 | <1% | 1,664 | $2K | |
| 84460 | <1% | 1,753 | $2K | |
| 84145 | <1% | 219 | $2K | |
| 84450 | <1% | 1,768 | $2K | |
| 81329 | <1% | 26 | $2K | |
| A0998 | Ambulance response and treatment, no transport | <1% | 28 | $2K |
| 99152 | <1% | 188 | $2K | |
| 85384 | <1% | 348 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 263 | $2K |
| 91300 | <1% | 18,162 | $2K | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 141 | $2K |
| 73120 | <1% | 42 | $2K | |
| 87088 | <1% | 582 | $2K | |
| 73620 | <1% | 62 | $2K | |
| 87641 | <1% | 321 | $2K | |
| 82040 | <1% | 1,839 | $2K | |
| 86710 | <1% | 254 | $1K | |
| 86923 | <1% | 160 | $1K | |
| 87640 | <1% | 332 | $1K | |
| 72170 | <1% | 63 | $1K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 643 | $1K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 604 | $1K |
| 71271 | <1% | 13 | $1K | |
| 80177 | <1% | 197 | $1K | |
| 84155 | <1% | 1,661 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 138 | $1K |
| 82140 | <1% | 242 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 556 | $1K |
| 78580 | <1% | 15 | $1K | |
| 86308 | <1% | 638 | $1K | |
| D0274 | Bitewings - four radiographic images | <1% | 161 | $1K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 2,948 | $1K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 413 | $1K |
| 73000 | <1% | 24 | $1K | |
| 76882 | <1% | 26 | $1K | |
| 86580 | <1% | 279 | $1K | |
| 94010 | <1% | 14 | $1K | |
| 90688 | <1% | 76 | $1K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 584 | $991.62 |
| 58300 | <1% | 33 | $991.52 | |
| 82657 | <1% | 278 | $985.33 | |
| 99001 | <1% | 801 | $931.91 | |
| 82010 | <1% | 224 | $890.94 | |
| 94726 | <1% | 34 | $855.67 | |
| 36600 | <1% | 108 | $848.64 | |
| 87529 | <1% | 54 | $832.25 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 104 | $811.80 |
| 80365 | <1% | 133 | $792.34 | |
| 80361 | <1% | 133 | $770.29 | |
| 84550 | <1% | 518 | $768.51 | |
| 80367 | <1% | 133 | $737.32 | |
| 90707 | <1% | 24 | $720.55 | |
| 82043 | <1% | 851 | $712.66 | |
| 86696 | <1% | 137 | $710.29 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,077 | $701.26 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 296 | $674.35 |
| 0082A | <1% | 25 | $664.65 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 24 | $662.90 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 460 | $660.41 |
| 36416 | <1% | 146 | $653.73 | |
| 82105 | <1% | 94 | $645.19 | |
| 80348 | <1% | 132 | $630.74 | |
| 70487 | <1% | 13 | $609.93 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 781 | $609.57 |
| 88173 | <1% | 12 | $601.27 | |
| 80356 | <1% | 132 | $599.60 | |
| 80354 | <1% | 131 | $583.12 | |
| 80358 | <1% | 133 | $583.12 | |
| 0073A | <1% | 15 | $572.93 | |
| 94645 | <1% | 28 | $535.06 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 391 | $525.75 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 15 | $515.62 |
| 87045 | <1% | 87 | $510.83 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 35 | $508.13 |
| 86039 | <1% | 95 | $505.27 | |
| 86695 | <1% | 137 | $498.19 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 138 | $485.46 |
| 85045 | <1% | 199 | $460.10 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 91 | $455.35 |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 16 | $437.92 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 139 | $413.81 |
| 0083A | <1% | 12 | $401.86 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 277 | $380.47 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 154 | $351.80 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 233 | $335.39 |
| 90649 | <1% | 173 | $331.18 | |
| 86481 | <1% | 12 | $327.14 | |
| 82784 | <1% | 91 | $310.49 | |
| 88302 | <1% | 29 | $308.40 | |
| 83020 | <1% | 53 | $302.79 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 12 | $294.32 |
| 84132 | <1% | 48 | $270.72 | |
| 83037 | <1% | 54 | $256.32 | |
| 82375 | <1% | 93 | $251.15 | |
| 85651 | <1% | 35 | $242.35 | |
| 87046 | <1% | 137 | $233.31 | |
| 90732 | <1% | 15 | $232.33 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 650 | $226.01 |
| 90633 | <1% | 12 | $224.41 | |
| 90687 | <1% | 31 | $211.60 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 97 | $208.41 |
| 87102 | <1% | 66 | $195.57 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 82 | $185.56 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 67 | $183.42 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 61 | $183.42 |
| 90734 | <1% | 83 | $182.86 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 53 | $165.98 |
| 86870 | <1% | 13 | $162.23 | |
| 89051 | <1% | 243 | $158.91 | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 12 | $157.49 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 15 | $150.26 |
| 86617 | <1% | 14 | $149.30 | |
| 86592 | <1% | 92 | $146.34 | |
| 84153 | <1% | 40 | $143.57 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 219 | $140.07 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 72 | $134.32 |
| 87081 | <1% | 25 | $132.30 | |
| 82950 | <1% | 91 | $125.58 | |
| 86880 | <1% | 26 | $119.47 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 40 | $89.15 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 54 | $83.17 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 41 | $81.80 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 64 | $80.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 26 | $78.98 |
| 84466 | <1% | 26 | $78.75 | |
| 84481 | <1% | 15 | $75.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 78 | $69.13 |
| 90619 | <1% | 29 | $68.85 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 26 | $60.95 |
| J7643 | Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram | <1% | 223 | $58.31 |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | <1% | 19 | $54.49 |
| 91307 | <1% | 762 | $51.00 | |
| G0008 | Administration of influenza virus vaccine | <1% | 207 | $45.29 |
| 85046 | <1% | 18 | $41.25 | |
| 87210 | <1% | 82 | $36.72 | |
| 87799 | <1% | 37 | $35.27 | |
| 83540 | <1% | 29 | $33.04 | |
| 83050 | <1% | 40 | $32.69 | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 15 | $27.50 |
| 83615 | <1% | 15 | $26.60 | |
| 82570 | <1% | 15 | $22.73 | |
| C9285 | Lidocaine 70 mg/tetracaine 70 mg, per patch | <1% | 37 | $20.46 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 32 | $19.80 |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 32 | $19.74 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 15 | $16.53 |
| 85014 | <1% | 34 | $13.18 | |
| 90662 | <1% | 29 | $12.12 | |
| 85018 | <1% | 34 | $11.82 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 20 | $10.32 |
| 91303 | <1% | 91 | $8.00 | |
| J3490 | Unclassified drugs | <1% | 18 | $5.35 |
| 91306 | <1% | 79 | $5.00 | |
| 91308 | <1% | 69 | $3.00 | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 16 | $3.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 12 | $1.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 21 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 12 | $0.00 |
| J1094 | Injection, dexamethasone acetate, 1 mg | 0% | 32 | $0.00 |
| OP636 | 0% | 200 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLOWE, GERRY (VP FOR FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Virtua - Memorial Hospital Burlington County, INC. | Mount Holly, NJ | $73.71M |
| Virtua - West Jersey Health System, INC. | Marlton, NJ | $2.39M |
| Virtua - Memorial Hospital of Burlington County, INC. | Mount Laurel, NJ | $300K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.